Skyrizi (risankizumab-rzaa) / Boehringer Ingelheim, AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

18 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
NCT02443298 / 2014-004932-20: Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Completed
2a
214
Canada, US, Europe, RoW
placebo, risankizumab, ABBV-066, BI 655066
AbbVie, Boehringer Ingelheim
Asthma
10/17
02/18
NCT02054481 / 2012-004384-48: BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

Checkmark
Feb 2016 - Feb 2016: 
Checkmark
Feb 2016 - Feb 2016: 
Checkmark
More
Completed
2
166
US, Canada, Europe
BI 655066, Ustekinumab
Boehringer Ingelheim
Psoriasis
11/14
07/15
NCT02047110 / 2013-003666-13: BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Checkmark Primary study outcome not met
Jul 2018 - Jul 2018: Primary study outcome not met
Completed
2
159
NA
placebo for risankizumab, risankizumab, ABBV-066, BI 655066, SKYRIZI
AbbVie, Boehringer Ingelheim
Ankylosing Spondylitis (AS)
03/15
07/16
NCT02031276 / 2013-002902-29: Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Checkmark Efficacy and safety data in Crohn's disease
Jul 2018 - Jul 2018: Efficacy and safety data in Crohn's disease
Checkmark Induction data in Crohn’s disease at DDW 2016
Apr 2016 - Apr 2016: Induction data in Crohn’s disease at DDW 2016
Completed
2
121
NA
risankizumab IV, BI 655066, ABBV-066, risankizumab SC, Placebo
AbbVie, Boehringer Ingelheim
Crohn Disease
12/15
11/16
NCT02719171 / 2015-003625-34: BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Completed
2
185
NA
risankizumab, BI 655066, ABBV-066, SKYRIZI, placebo for risankizumab
AbbVie, Boehringer Ingelheim
Arthritis, Psoriatic
05/17
08/17
NCT03000075: BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
182
NA
risankizumab, ABBV-066, BI 655066, placebo for risankizumab
AbbVie, Boehringer Ingelheim
Psoriasis
09/17
06/18
NCT02986373 / 2016-003113-94: A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Checkmark In psoriatic arthritis
Oct 2017 - Oct 2017: In psoriatic arthritis
Completed
2
145
NA
risankizumab, ABBV-066, BI 655066, SKYRIZI
AbbVie
Psoriatic Arthritis
07/18
07/18
NCT02203851 / 2014-001687-36: Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
110
NA
Risankizumab, BI 655066, ABBV-066, SKYRIZI
AbbVie, Boehringer Ingelheim
Psoriasis
09/18
09/18
NCT02513459 / 2015-001834-15: A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Hourglass Jan 2017 - Dec 2017 : Data from a trial in Crohn’s disease
Completed
2
65
Europe, Canada, US, RoW
Risankizumab 600 mg IV, BI 655066, ABBV-066, Risankizumab 180 mg SC
AbbVie, Boehringer Ingelheim
Crohn Disease
06/19
06/19
NCT03706040 / 2021-002203-34: A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Completed
2
172
Canada, Japan, US, RoW
Placebo, Risankizumab, ABBV-066, BI 655066
AbbVie
Dermatitis
10/20
04/21
DETERMINED 1, NCT03926169 / 2019-000122-21: A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Completed
2
243
Europe, Canada, Japan, US, RoW
Risankizumab, ABBV-066, SKYRIZI, Placebo for risankizumab
AbbVie
Hidradenitis Suppurativa
02/21
08/21
NCT04583956: ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

Completed
2
214
US
Placebo, Remdesivir, Risankizumab
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
09/21
09/21
KNOCKOUT, NCT05283135: High Dose Risankizumab for Psoriasis

Completed
2
20
US
risankizumab, Skyrizi
Oregon Medical Research Center, AbbVie
Psoriasis
08/23
07/24
NCT06548542: Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
2
500
Europe, Canada, US, RoW
Risankizumab, Lutikizumab, ABBV-382
AbbVie
Crohn's Disease
12/27
08/28
NCT06865105: Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Recruiting
2
120
Europe, Canada, US, RoW
Lutikizumab, Risankizumab
AbbVie
Psoriatic Arthritis
12/27
01/28
NCT07138898: Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not yet recruiting
2
80
US
Methotrexate, Sulfasalazine, Hydroxychloroquine, Plaquenil, Leflunomide, Arava, Azathioprine, Imuran, Mycophenolate, Cellcept, Cyclosporine, Tacrolimus, Etanercept, Enbrel, Adalimumab, Humira, Golimumab, Simponi, Certolizumab, Cimzia, Infliximab, Remicaide, Rituximab, Rituxan, Belimumab, Benlysta, Tocilizumab, Actemra, Anakinra, Kineret, Canakinumab, Ilaris, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Bimekizumab, Bimzelx, Ustekinumab, Stelara, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tofacitinib, Xeljanz, Upadacitinib, Rinvoq
NYU Langone Health
Rheumatic Disease
09/27
09/27
NAVIGATE, NCT06606808: Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

Recruiting
1/2
18
Europe
Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg, Risankizumab-800CW optimal dose
University Medical Center Groningen
Ulcerative Colitis (UC), Crohn Disease (CD)
08/25
12/25
VOYAGER, NCT07258641: Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

Not yet recruiting
1/2
30
Europe
25mg adalimumab-680LT and 15/25 mg risankizumab-800CW, Adalimumab-680LT 25mg, Risankizumab-800CW 15 mg/25 mg
University Medical Center Groningen
Ulcerative Colitis (UC), Crohn Disease (CD)
12/27
04/28

Download Options